The maximum amount that the New Brunswick Drug Plans will reimburse for one unit of a drug product in this category (e.g. pharmaceutical equivalent, pharmaceutical alternative, interchangeable) is the Maximum Allowable Price (MAP) specified in the MAP List.
- MAP prices that are highlighted in grey have been increased due to shortages of products in the category.
- Product names that are highlighted in grey indicate that the manufacturer has not confirmed the MAP price for all package sizes of the product.
MAP List: PDF | XLS
The MAP for each category is determined by calculating a percentage of the price of the reference brand name drug.
If there is no drug, other than the original product, with a Notice of Compliance on June 1, 2013:
Solid Oral Dosage Form: 25% of the MLP of the original product as of the date a Notice of Compliance is issued for the first product in a MAP category, other than the original product
Non-Solid Oral Dosage Form: 35% of the MLP of the original product as of the date a Notice of Compliance is issued for the first product in a MAP category, other than the original product
If there is another drug, other than the original product, with a Notice of Compliance on June 1, 2013:
Solid Oral Dosage Form: 25% of the original product price as of January 1, 2010
Non-Solid Oral Dosage Form: 35% of the original product price as of January 1, 2010
pan-Canadian Competitive Value Price Initiative for Generic Drugs
Provinces and territories work together to lower generic drug prices through the Council of the Federation’s pan-Canadian Competitive Value Price Initiative for Generic Drugs. Under this initiative, the prices of certain generic drugs are set at 10 or 18% of the brand name drug price.
Exceptions
The MAP for a category may be varied if the proposed price is not higher than the price in another Canadian jurisdiction and one or more of the following conditions exists:
- the manufacturer provides documentation indicating that a different unit price should be established;
- the manufacturer’s list price for the original product has changed;
- the original product is no longer marketed in Canada or another product with similar ingredients, strength and form has received a notice of compliance;
- it is justified having regard to market conditions; or
- it is justified in the public interest having regard to the safety of members of the Plan, access to the drug or costs to the Plan.